α-PiHP

coronary artery disease, cardiac arrhythmias, cardiomyopathy, uncontrolled hypertension

α-PiHP produces cardiovascular stress exceeding that of equi-dose cocaine, with more sustained blood pressure elevation documented in the De la Rosa 2025 observational study. Pre-existing coronary artery disease, arrhythmias, cardiomyopathy, or uncontrolled hypertension substantially increase the risk of acute cardiac events including sudden cardiac arrest, which has been documented in postmortem case series.

epilepsy, seizure disorders

No α-PiHP-specific seizure cases are documented, but sympathomimetic stimulants as a class lower seizure threshold. Individuals with epilepsy or other seizure disorders face elevated risk.

schizophrenia, schizoaffective disorder, psychotic spectrum disorders

α-PiHP's selective dopaminergic mechanism poses specific risk for psychotic decompensation in predisposed individuals. Hallucinations, delusions, and paranoia are documented at high doses in case reports and the ECDD repository. Individuals with schizophrenia, schizoaffective disorder, or other psychotic spectrum conditions face amplified risk.

Stimulant drugs with high dopaminergic activity can precipitate manic or mixed episodes in individuals with bipolar disorder. No α-PiHP-specific case reports exist, but the mechanism-based risk is well established for the stimulant class.

generalized anxiety disorder, panic disorder, PTSD

α-PiHP produces anxiety and paranoia at recreational doses, documented in intoxication case reports and consistent with NET-mediated noradrenergic arousal. Individuals with severe generalized anxiety disorder, panic disorder, or PTSD may experience exacerbation of symptoms.

Life-threatening rhabdomyolysis with acute kidney injury has been documented following massive oral ingestion (T'kind 2024). Pre-existing renal impairment reduces the kidney's capacity to tolerate myoglobin-mediated nephrotoxicity, increasing the risk of acute kidney injury progression.

Standard sympathomimetic stimulant contraindication. Hyperthyroidism produces baseline adrenergic excess; adding a potent NET/DAT inhibitor compounds cardiovascular stress and thermoregulatory instability.

No reproductive toxicity data exist for α-PiHP. Sympathomimetic stimulants pose established risks to fetal cardiovascular development and placental perfusion through catecholamine-mediated vasoconstriction. Use during pregnancy or lactation is contraindicated.

Concurrent use with any monoamine oxidase inhibitor (MAOI) — including irreversible (phenelzine, tranylcypromine), reversible (moclobemide), or dietary supplement MAOIs — is contraindicated due to the risk of hypertensive crisis from dual blockade of monoamine degradation and reuptake.